Zai Lab announced that China’s National Medical Products Administration has approved the Biologics License Application for VYVGART a first-in-class neonatal Fc receptor antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. Zai Lab will now work with the National Healthcare Security Administration for NRDL inclusion to enable broad access for patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZLAB:
- Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
- Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
- Zai Lab announces China NMPA acceptance of repotrectinib NDA
- Zai Lab price target lowered to $62.50 from $75 at BofA
- Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies